A Phase 1 study of LY4086940 in healthy and overweight/obese participants

Study Description

A study to evaluate the safety and how the body processes a new investigational drug (LY4086940) in healthy participants and those with overweight, obesity, or type 2 diabetes

Study Details

Registry ID:

NCT06945419

Conditions:

Healthy, Overweight, Obesity, Type 2 Diabetes

Phase:

Phase 1

Target Enrollment:

219 participants

Start Date:

April 23, 2025

Age Range:

18–65 years

Healthy Volunteers:

No

Study Locations (6 sites)

• Clinical Pharmacology of Miami
  Miami, FloridaUnited States, United States
• Fortrea Clinical Research Unit
  Daytona Beach, FloridaUnited States, United States
• CenExel iResearch, LLC
  Decatur, GeorgiaUnited States, United States
• Fortrea Clinical Research Unit
  Dallas, TexasUnited States, United States
• Endeavor Clinical Trials
  San Antonio, TexasUnited States, United States
• Lilly Centre for Clinical Pharmacology
  SingaporeSingapore, Singapore

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →